Is PFE a good stock to buy?
Pfizer Inc. · end-of-day data as of Nov 13, 2026
- FCF yield+7.2%
- Trendbullish
- MAs3 of 4
- Sector▲ +15.9%
- Earnings in81d
- P/E41.5x
- RSI48
- Support-2.4%
- Resistance+4.4%
- Off 52w high-8.1%
- Volume0.6x
- Bollingerlower half
- News
- ConsensusHold · 28
- PT$29.43 +1.9%
- 52w range$24–$31
- ATR+2.4%
- Off ATH-53.2%
- InsidersNone in 90d
- P/E vs own+47.8%
- P/E vs sector+28.7%
- MACD-0.16
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Pfizer a good stock to buy?
Pfizer is strong on 2 of the 5 questions about the business; weak on demand. The price is high: 41.5 times its earnings, above its 3-year median of 18.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand shrinking
- Advantage some edge
- Economics very profitable
- Execution delivers
- Fragility some risks
- Price expensive
PFE sales growth revenue growth
-15%a year, for the last 3 yearsPfizer's sales fell 15% a year for 3 years, to $62.58B in fiscal 2025.
PFE analysts' forecast revenue estimates
+1%the sales they expect next fiscal year, on the lastAnalysts expect Pfizer's sales to grow 1% to $63B in fiscal 2026 (18 analysts).
PFE competitors
pretickt analysis+1%its sales in 12 months, on a year before
Pfizer's sales grew 1% in the 12 months to Sep 27, 2026, slower than Amgen (+8%), Gilead (+7%), Merck (+5%) and Bristol-Myers Squibb (+4%).
PFE return on capital ROIC
pretickt analysis10%earned before tax on the money invested in itPfizer earned 10% before tax on the capital invested in it in the 12 months to Sep 27, 2026; Amgen 25%, Bristol-Myers Squibb 23%, Merck 12% and Gilead -4%.
PFE margin on each sale gross margin
73%left after making the productPfizer kept 73% of each sale after making the product in the 12 months to Sep 27, 2026; its competitors' median is 75%.
PFE margin after costs profit margin
24%of sales left after running the businessPfizer's operating margin was 24% in the 12 months to Sep 27, 2026, against 37% in fiscal 2022.
PFE cash generated free cash flow
$11.79Bcash left after investing, last 12 monthsPfizer generated $11.79B of free cash flow in the 12 months to Sep 27, 2026, more than its reported profit.
PFE earnings vs estimates
8 of 8quarters above the analysts' estimatePfizer beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 3, 2026.
PFE insider buying
+$2.83Mbought, net, by its executives in 12 monthsPfizer's executives and directors bought a net $2.83M of shares in the 12 months to Nov 13, 2026 ($2.96M bought, $135K sold).
PFE number of employees
-7%fewer people in a yearPfizer had 75,000 employees at the end of fiscal 2025, 7% fewer than a year before.
PFE CEO pay
$27.59Mfor fiscal 2025, 67% of it in stock and optionsPfizer paid its CEO $27.59M for fiscal 2025, 67% of it in stock and options.
PFE financial health Altman Z-score
2.1Altman Z-score, safe above 3Pfizer's Altman Z-score is 2.1 (Nov 13, 2026), between 1.8 and 3, the grey zone.
PFE quality checks Piotroski score
5 of 9checks passedPfizer passes 5 of the 9 Piotroski checks in the 12 months to Sep 27, 2026; it misses on return on assets, long-term debt, new shares and gross margin.
PFE biggest customers
54%of sales from its 3 biggest customersMcKesson, Cencora and Cardinal Health made 54% of Pfizer's sales in fiscal 2025.
PFE in past recessions
pretickt analysis0%its sales in the worst onePfizer's sales did not fall in any of the last 2 US recessions (2008–09 and 2020).
PFE price vs profit P/E ratio
41.5×a year's earningsPfizer's P/E ratio is 41.5 (Nov 13, 2026), above its 3-year median of 18.6.
PFE price vs competitors
pretickt analysis41.5×a year's earnings, against its competitorsInvestors pay 41.5 times Pfizer's earnings (Nov 13, 2026), more than for Amgen (27.0) and Bristol-Myers Squibb (14.1), less than for Merck (152.3).
PFE analysts' target price target
+2%to their average targetAnalysts' average price target for Pfizer is $29.43, 2% above the Nov 13, 2026 close of $28.89.
PFE growth priced in fair value
pretickt analysis+2%a year, for ten years, to be worth the priceAt $28.89 a share, Pfizer's free cash flow must grow about 2% a year for ten years to be worth the price (Nov 13, 2026).
What is Pfizer's P/E ratio?
Pfizer's P/E ratio is 41.5 (Nov 13, 2026), above its 3-year median of 18.6. Investors pay 41.5 times Pfizer's earnings (Nov 13, 2026), more than for Amgen (27.0) and Bristol-Myers Squibb (14.1), less than for Merck (152.3).
Who are Pfizer's biggest competitors?
pretickt compares Pfizer with Gilead, Bristol-Myers Squibb, Amgen and Merck. Pfizer's sales grew 1% in the 12 months to Sep 27, 2026, slower than Amgen (+8%), Gilead (+7%), Merck (+5%) and Bristol-Myers Squibb (+4%).
Is Pfizer profitable?
Pfizer's operating margin was 24% in the 12 months to Sep 27, 2026, against 37% in fiscal 2022. Pfizer generated $11.79B of free cash flow in the 12 months to Sep 27, 2026, more than its reported profit.
Are insiders buying Pfizer stock?
Pfizer's executives and directors bought a net $2.83M of shares in the 12 months to Nov 13, 2026 ($2.96M bought, $135K sold).
Who owns Pfizer stock?
2,965 institutions hold 68% of Pfizer's shares (Jun 30, 2026); BlackRock, Vanguard and State Street added shares that quarter.
How many employees does Pfizer have?
Pfizer had 75,000 employees at the end of fiscal 2025, 7% fewer than a year before.
Who are Pfizer's biggest customers?
McKesson, Cencora and Cardinal Health made 54% of Pfizer's sales in fiscal 2025. Cencora, Cardinal Health and McKesson, customers of Pfizer, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.